» Articles » PMID: 37803394

The Response to Substandard and Falsified Medical Products in Francophone Sub-Saharan African Countries: Weaknesses and Opportunities

Abstract

Assuring the quality of medical products manufactured, imported or distributed in francophone sub-Saharan Africa remains a challenge, despite positive signals like the growing engagement in the benchmarking of regulatory authorities and -particularly- in the establishment of the African Medicines Agency. In this short report, we describe the existing activities to prevent, detect and respond to substandard and falsified products (SF) in this region, either through African multilateral organizations and initiatives led by the World Health Organization, or through the contribution of other stakeholders, such as local universities and procurement agencies. We underline that these emerging local stakeholders may play a pivotal role to guide and inform the national regulatory authorities about the prevalence and patterns of SF medical products, complementing the market surveillance and control, and building awareness of the importance of pharmaceutical quality assurance for public health.

Citing Articles

Quality of Essential Medicines from Different Sources in Enugu and Anambra, Nigeria.

Gabel J, Lachele M, Sander K, Gnegel G, Sunny-Abarikwu N, Ohazulike R Am J Trop Med Hyg. 2024; 111(1):179-195.

PMID: 38740019 PMC: 11229646. DOI: 10.4269/ajtmh.23-0837.

References
1.
Newton P, Caillet C, Guerin P . A link between poor quality antimalarials and malaria drug resistance?. Expert Rev Anti Infect Ther. 2016; 14(6):531-3. DOI: 10.1080/14787210.2016.1187560. View

2.
Gnegel G, Hafele-Abah C, Neci R, Heide L . Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab. Sci Rep. 2022; 12(1):13095. PMC: 9338985. DOI: 10.1038/s41598-022-17123-0. View

3.
Newton P, Bond K . Global access to quality-assured medical products: the Oxford Statement and call to action. Lancet Glob Health. 2019; 7(12):e1609-e1611. DOI: 10.1016/S2214-109X(19)30426-7. View

4.
Waffo Tchounga C, Sacre P, Ciza P, Ngono R, Ziemons E, Hubert P . Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic. J Pharm Biomed Anal. 2020; 194:113761. PMC: 7659915. DOI: 10.1016/j.jpba.2020.113761. View

5.
Amari A, Ouattara S, Koffi A . [Descriptive study of the regulation N°06/2010/CM/UEMOA on procedures followed for registration of pharmacticals for human use in UEMOA member states]. Mali Med. 2018; 27(2):6-12. View